cannabidiol-loaded liposomes / Innocan Pharma - LARVOL DELTA

FDA Has Granted Innocan Pharma a Meeting Date for LPT-CBD for Chronic Pain (PRNewswire) - "Innocan Pharma Corporation...is pleased to announce significant advancements in the regulatory process for its Liposome-Cannabidiol (LPT-CBD) technology, which provides an innovative solution in non-opioid pain management. The U.S. Food and Drug Administration ('FDA') has granted Innocan an Investigational New Drug ('IND') number and approved an initial meeting with the Company to discuss the strategic path forward. The meeting with the FDA has been set for July 31, 2024, where Innocan will present its preclinical results and proposed clinical development plan. This meeting is key to launching human clinical trials for the LPT-CBD injectable drug, developed to provide a novel treatment option for chronic pain."

FDA event • IND • Pain

Innocan Pharma Initiates FDA Approval Process for Liposome Injection Therapy for Chronic Pain (PRNewswire) - "Innocan Pharma Corporation...is pleased to announce that is has reached a key milestone: the Company submitted its letter of application for a Pre-IND meeting, the first phase in the FDA approval process in the United States for Innocan's Liposome-Cannabidiol (LPT-CBD) injectable treatment of chronic pain....At the Pre-IND meeting, the objective will be to obtain guidance from the FDA on the preclinical and clinical development plan, enabling the initiation of an Investigational New Drug (IND) program in the United States."

FDA event • Pain

Innocan Pharma Reports Another Successful Result from a Pre-Clinical Study on a Dog Suffering from Refractory (Drug-Resistant) Epilepsy Following LPT Treatment (Streetinsider.com) - "Innocan Pharma Corporation...is pleased to announce additional positive results in a new preclinical trial involving a dog with refractory (drug-resistant) epilepsy. In this trial, the dog was treated with Innocan Pharma's LPT (CBD Loaded Liposome Platform) injections....During the several months of the trial, the dog did not require hospitalization. Additionally, since the last LPT injection, the dog did not experience a seizure for a duration of 9.5 weeks."

Preclinical • CNS Disorders • Epilepsy

Innocan Reports Positive Results from Recent Preclinical Trial on Epileptic Seizures On a Dog using LPT: "Since The Last LPT injection, Paco (dog) Has Not Had a Seizure for Over 10 weeks" (Yahoo Finance) - "Innocan Pharma Corporation...is pleased to announce positive results in a preclinical trial involving a dog with refractory (drug-resistant) epilepsy. In this trial, the dog was treated with Innocan Pharma's LPT (CBD Loaded Liposome Platform) injections. The results demonstrated that the frequency and the intensity of the dog's epileptic seizures decreased significantly....'Our innovation and IP brings effective results in the pre-clinical stage, and Innocan is determined to complete significant sets of lab experiments soon.'"

Preclinical • CNS Disorders • Epilepsy

Innocan Pharma’s CBD-Loaded Liposome Platform Technology Demonstrates a Prolonged Release of CBD in Large Animals (Yahoo Finance) - "Innocan Pharma Corporation...is pleased to announce that it has conducted a recent experimental study of its CBD-loaded liposome technology (LPT) on large animals that demonstrated a similar pharmacokinetic profile as was demonstrated in a previous small animal study. This result is expected to bring the Company closer to clinical trials in humans. Pharmacokinetics (PK) determines the profile of drug concentrations in the blood as a function of time from the moment that it was administered thus indicating drug efficacy."

Preclinical • CNS Disorders • Epilepsy